Product Type
Fc Silent Antibody
Description
The Fc-mediated effector functions of antibodies include antibody-dependent cellular cytotoxicity (ADCC), antibody-dependent cellular phagocytosis (ADCP), and complement-dependent cytotoxicity (CDC), and have been shown to be crucial for the therapeutic efficacy of most clinically approved antibodies. However, engaging immune effectors through FcγR and complement interactions may be detrimental to certain mAb mechanisms of action and so Fc-null or -silenced antibodies may be desired.
Creative Biolabs uses site-directed mutagenesis technology to generate Fc-silenced antibody with reduced effector functions. The mutated Fc domains eliminate the binding of Fc receptors (FcγR, FcR), thereby leading to a significant reduction in ADCC and CDC in comparison to WT IgG.
Immunogen
SKBR3 human breast tumour cells were injected into BALB/c mice. The hybridomas generated from the mice spleen cells were then screen for antibodies reactive to c-erbB-2 using immunofluorescence.
Source
This chimeric human antibody was made using the variable domain sequences of the original Mouse IgG1 format, for improved compatibility with existing reagents, assays and techniques.
Application
IF, IP, FC, fusion
Storage Instructions
Store at 4⁰C for up to 3 months. For longer storage, aliquot and store at -20⁰C.
Alternative Names
ERBB2, CD340, HER-2, HER-2/neu, HER2, MLN 19, NEU, NGL, TKR1, erb-b2 receptor tyrosine kinase 2
